Analysis of the Effects of Bevacizumab Combined with Chemoradiotherapy on VEGF, bFGF, and Let-7 Levels in Non-Small Cell Lung Cancer and the Factors Influencing Therapeutic Efficacy: A Retrospective Cohort Study
Xiang-Chong Luo,Peng Tang,Pei-Xiong Zhong
DOI: https://doi.org/10.2147/ijgm.s488849
IF: 2.145
2024-12-04
International Journal of General Medicine
Abstract:Xiang-Chong Luo, 1, &ast Peng Tang, 2, &ast Pei-Xiong Zhong 3 1 Department of Cardiothoracic Surgery, The Second People's Hospital of Qujing City, Qujing City, Yunnan Province, People's Republic of China; 2 Department of TCM Pharmacy, Chengdu Integrated TCM and Western Medicine Hospital, Chengdu, People's Republic of China; 3 Department of Respiratory and Critical Care Medicine, Haikou Third People's Hospital, Haikou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Pei-Xiong Zhong, Email Objective: To explore the influence of bevacizumab combined with chemoradiotherapy on VEGF, bFGF, and Let-7 in patients with non-small cell lung cancer (NSCLC), and to analyze the factors affecting its efficacy. Methods: Totally 150 patients with non-small cell lung cancer (NSCLC) treated in our hospital from November 2018 to November 2023 were retrospectively analyzed. The serum levels of VEGF, bFGF, and Let-7 were collected and compared. Patients were divided into good efficacy and poor efficacy groups based on short-term efficacy, and logistic regression analysis was used to analyze the factors affecting efficacy. Results: Before treatment, there was no significant difference in the levels of VEGF, bFGF, and Let-7 between the two groups (P> 0.05). After treatment, the levels of VEGF, bFGF, and Let-7 in both groups improved compared to before treatment, and compared with the control group, the study group had lower levels of VEGF and bFGF, and higher levels of Let-7, with statistically significant differences (all P< 0.05). Multifactorial logistic regression analysis revealed that the course of disease, tumor diameter, and treatment regimen were independent factors influencing the therapeutic efficacy of NSCLC (all P< 0.05). Conclusion: For patients with NSCLC, the treatment regimen of bevacizumab combined with chemoradiotherapy can achieve better efficacy, with a higher objective response rate, effectively reduce the level of vascular endothelial growth factor, increase Let-7 level, and ensure safety. In addition, disease course, tumor diameter, and treatment regimen are independent factors affecting the efficacy of NSCLC. Therefore, these factors should be comprehensively considered when formulating treatment plans to ensure the best therapeutic effect. Keywords: bevacizumab, non-small cell lung cancer, efficacy, adverse reactions, influencing factors Lung cancer stands as a formidable health challenge, characterized by a substantial incidence rate and an alarming mortality rate. Indeed, it has emerged as the leading cause of cancer-associated deaths worldwide. Among the diverse subtypes, non-small cell lung cancer (NSCLC) predominates, accounting for more than 80% of diagnosed cases. 1 NSCLC, characterized by its aggressive invasiveness and proclivity for metastasis, poses significant challenges due to the development of resistance mechanisms. These complexities have a profound impact on patient prognosis and necessitate innovative approaches to enhance treatment outcomes. 2 Concurrent chemoradiotherapy is a standard treatment regimen for NSCLC, particularly indicated for locally advanced stage III disease. It has been shown to inhibit tumor growth and extend patient survival by controlling locoregional disease progression. 3 VEGF is the most important pro-angiogenic factor in the angiogenesis process in lung cancer patients. VEGF is expressed in both small cell lung cancer and NSCLC, and overexpression of VEGF is associated with poor prognosis of lung cancer. 4 Bevacizumab is the first molecular targeted drug used in the treatment of NSCLC. 5 By binding to VEGF, bevacizumab can block tumor angiogenesis, inhibit tumor blood supply, and restrict tumor nutrition and oxygen supply, thereby inhibiting tumor growth and spread. 6 Studies have indicated that bevacizumab can improve the delivery of chemotherapy drugs to tumor tissues, enhancing the efficacy of chemotherapy. 7,8 Therefore, bevacizumab is often used in combination with chemotherapy drugs, and compared to traditional chemotherapy drugs, the adverse reactions and side effects of bevacizumab combined with chemotherapy drugs are relatively minimal. 9 B-fibroblast growth factor (b-FGF) is a growth factor that plays an important role in cell proliferation, differentiation, and angiogenesis. Studies have shown that b-FGF also plays a key role in the invasion and metastasis of NSCLC. MicroRNAs (miRNAs) are a class of non-coding small RNA molecules consisting of 18–25 nucleotides. It is generally believed that miRNAs play a crucial regulatory role in th -Abstract Truncated-
medicine, general & internal